… of metastatic castration-sensitive prostate cancer, with particular attention to … apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide (Nubeqa), were … ongoing evolution of metastatic prostate cancer management. While acknowledging that …

… management of metastatic castration-sensitive prostate cancer (mCSPC). The conversation … apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide (Nubeqa) were … standing role in metastatic prostate cancer. Panelists emphasized its effectiveness …

… across the spectrum of advanced prostate cancer. Building on their prior … abiraterone acetate (Zytiga)—for very high-risk localized prostate cancer. Patel explains … insights for clinicians navigating complex prostate cancer cases and underscores how …

… mutated metastatic castration-sensitive prostate cancer (mCSPC). Akeega, … ’s androgen-directed prostate cancer med Zytiga (abiraterone acetate) … options across the prostate cancer continuum," the … treatment landscape for prostate cancer has advanced in …

… multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs … prostate cancer, where it already has a strong presence with drugs like Zytiga …

… rapidly evolving management of metastatic prostate cancer, emphasizing practical decision-making, … patients with metastatic hormone-sensitive prostate cancer (mHSPC). Participants reaffirmed … steered toward abiraterone acetate (Zytiga) due to cost advantages …

… locally advanced prostate cancer and high-risk biochemically relapsed prostate cancer. The … analog, apalutamide, abiraterone acetate (Zytiga), and prednisone for 12 … clinically localised, and locally advanced prostate cancer: ENZARAD (ANZUP 1303). Presented …

… patients with prostate cancer]. Unequivocally in metastatic castration-resistant prostate cancer, they … combination with abiraterone acetate (Zytiga) and prednisone for the … patients with metastatic castration-sensitive prostate cancer (mCSPC) were presented, …

… to managing metastatic castration-sensitive prostate cancer (mCSPC). The discussion focused on … (Xtandi), apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide—were evaluated based …

… in-class approach to prostate cancer could overcome drug … other prostate cancer therapies are the CYP17 inhibitor Zytiga, and … androgen receptor on prostate cancer cells, bringing that … metastatic castration-resistant prostate cancer that has progressed …